-

Thermo Fisher Scientific Announces Expansion of Bioanalytical Laboratory Services in Europe

The PPD clinical research business joins GoCo Health Innovation City in Gothenburg, Sweden

WILMINGTON, N.C.--(BUSINESS WIRE)--The PPD™ clinical research business of Thermo Fisher Scientific, the world leader in serving science, announced today the expansion of its global laboratory services with a new bioanalytical lab in GoCo Health Innovation City in Gothenburg, Sweden, that will serve pharmaceutical and biotech customers with advanced laboratory services and leading-edge instrumentation across all phases of pharmaceutical development to help deliver life-changing medicines to patients worldwide.

The new 29,000-square-foot laboratory will be adjacent to the Gothenburg strategic research and development site of the global pharmaceutical company AstraZeneca, which has been instrumental in the development of GoCo Health Innovation City. Steptura, a joint real estate company among Next Step Group, Balder and Vectura Fastigheter, designed the life science and global research cluster in Sweden to attract researchers and entrepreneurs from around the world and to accelerate health innovation.

The PPD clinical research business will expand its bioanalytical capabilities to include comprehensive and full-service solutions, encompassing both small and large molecules, biomarkers and novel modalities. Service offerings will include a wide range of advanced technologies and methodologies, such as cell-based assays, chromatography, flow cytometry, immunochemistry and molecular genomics.

“We are thrilled to expand our bioanalytical footprint in Europe – in the collaborative and innovative environment of GoCo Health Innovation City – as we deploy the most technologically advanced systems to develop assays supporting early discovery and subsequently apply them for testing of clinical trial samples across every stage of drug development for our customers,” said Leon Wyszkowski, president, analytical services, clinical research, Thermo Fisher Scientific. “Our presence in Sweden will support our customers with accurate and timely data, empowering them to make informed decisions, as we advance Thermo Fisher’s Mission to enable our customers to make the world healthier, cleaner and safer.”

Jacob Torell, chief executive officer, Steptura, said, “We are incredibly excited to welcome Thermo Fisher Scientific to GoCo Health Innovation City. Their establishment and presence here underscore our commitment to fostering a dynamic ecosystem where cutting-edge technology and brilliant minds come together to shape the future of health innovation.”

The expansion will add up to 140 highly skilled scientists and laboratory support professionals, ranging from entry-level bench positions to general manager. The new lab, which is expected to be completed in the fourth quarter of 2025, will be equipped with state-of-the-art instrumentation, enabling a wide range of GLP-compliant bioanalytical capabilities. This advanced technology will facilitate the delivery of rapid and reliable bioanalytical assay services across all stages of drug development, from preclinical studies to post-approval studies.

In addition to the new lab in Sweden, the business operates a global network of GMP (good manufacturing practices), central, bioanalytical and vaccine science laboratories with operations based in Middleton, Wisconsin, Highland Heights, Kentucky, Richmond, Virginia, Athlone, Ireland, Brussels, Belgium, Singapore and Suzhou, China.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:
Name: Nadine Maeser
Email: nadine.maeser@ppd.com
media@ppd.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
The PPD™ clinical research business of Thermo Fisher Scientific announced the expansion of its global laboratory services in Gothenburg, Sweden.
Release Versions

Contacts

Media:
Name: Nadine Maeser
Email: nadine.maeser@ppd.com
media@ppd.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom